• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对铜死亡诱导剂和抑制剂的新见解。

Novel insights into cuproptosis inducers and inhibitors.

作者信息

Zhang Ligang, Deng Ruiting, Liu Lian, Du Hongli, Tang Dongsheng

机构信息

Gene Editing Technology Center of Guangdong Province, School of Medicine, Foshan University, Foshan, China.

School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.

出版信息

Front Mol Biosci. 2024 Nov 26;11:1477971. doi: 10.3389/fmolb.2024.1477971. eCollection 2024.

DOI:10.3389/fmolb.2024.1477971
PMID:39659361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11628392/
Abstract

Cuproptosis is a new pattern of Cu-dependent cell death distinct from classic cell death pathways and characterized by aberrant lipoylated protein aggregation in TCA cycle, Fe-S cluster protein loss, HSP70 elevation, proteotoxic and oxidative stress aggravation. Previous studies on Cu homeostasis and Cu-induced cell death provide a great basis for the discovery of cuproptosis. It has gradually gathered enormous research interests and large progress has been achieved in revealing the metabolic pathways and key targets of cuproptosis, due to its role in mediating some genetic, neurodegenerative, cardiovascular and tumoral diseases. In terms of the key targets in cuproptosis metabolic pathways, they can be categorized into three types: oxidative stress, mitochondrial respiration, ubiquitin-proteasome system. And strategies for developing cuproptosis inducers and inhibitors involved in these targets have been continuously improved. Briefly, based on the essential cuproptosis targets and metabolic pathways, this paper classifies some relevant inducers and inhibitors including small molecule compounds, transcription factors and ncRNAs with the overview of principle, scientific and medical application, in order to provide reference for the cuproptosis study and target therapy in the future.

摘要

铜死亡是一种新的铜依赖性细胞死亡模式,不同于经典的细胞死亡途径,其特征是三羧酸循环中异常的脂酰化蛋白聚集、铁硫簇蛋白丢失、热休克蛋白70升高、蛋白毒性和氧化应激加剧。先前关于铜稳态和铜诱导细胞死亡的研究为铜死亡的发现提供了重要基础。由于其在介导某些遗传、神经退行性、心血管和肿瘤疾病中的作用,它逐渐引起了巨大的研究兴趣,并且在揭示铜死亡的代谢途径和关键靶点方面取得了很大进展。就铜死亡代谢途径中的关键靶点而言,它们可分为三种类型:氧化应激、线粒体呼吸、泛素-蛋白酶体系统。并且针对这些靶点开发铜死亡诱导剂和抑制剂的策略也在不断改进。简而言之,基于铜死亡的关键靶点和代谢途径,本文对一些相关的诱导剂和抑制剂进行了分类,包括小分子化合物、转录因子和非编码RNA,并概述了其作用原理、科学和医学应用,以便为未来的铜死亡研究和靶向治疗提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/7101514575b5/fmolb-11-1477971-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/96978fcf3f82/fmolb-11-1477971-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/e4d45e161475/fmolb-11-1477971-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/403e2e9dc01a/fmolb-11-1477971-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/89b6580d6555/fmolb-11-1477971-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/7101514575b5/fmolb-11-1477971-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/96978fcf3f82/fmolb-11-1477971-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/e4d45e161475/fmolb-11-1477971-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/403e2e9dc01a/fmolb-11-1477971-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/89b6580d6555/fmolb-11-1477971-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43fe/11628392/7101514575b5/fmolb-11-1477971-g005.jpg

相似文献

1
Novel insights into cuproptosis inducers and inhibitors.对铜死亡诱导剂和抑制剂的新见解。
Front Mol Biosci. 2024 Nov 26;11:1477971. doi: 10.3389/fmolb.2024.1477971. eCollection 2024.
2
Recent progress of methods for cuproptosis detection.铜死亡检测方法的最新进展。
Front Mol Biosci. 2024 Sep 4;11:1460987. doi: 10.3389/fmolb.2024.1460987. eCollection 2024.
3
Copper homeostasis and cuproptosis in health and disease.铜稳态和铜死亡在健康和疾病中的作用。
Signal Transduct Target Ther. 2022 Nov 23;7(1):378. doi: 10.1038/s41392-022-01229-y.
4
Inducers of Autophagy and Cell Death: Focus on Copper Metabolism.自噬与细胞死亡的诱导剂:聚焦于铜代谢
Ecotoxicol Environ Saf. 2025 Jan 15;290:117725. doi: 10.1016/j.ecoenv.2025.117725. Epub 2025 Jan 16.
5
Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.人类恶性肿瘤中的铜代谢与铜死亡:揭示复杂相互作用以获得治疗见解。
Heliyon. 2024 Mar 7;10(5):e27496. doi: 10.1016/j.heliyon.2024.e27496. eCollection 2024 Mar 15.
6
Research progress on cuproptosis and copper related anti-tumor therapy.铜死亡与铜相关抗肿瘤治疗的研究进展
Discov Oncol. 2025 Apr 21;16(1):584. doi: 10.1007/s12672-025-02335-3.
7
Copper homeostasis and cuproptosis in gynecological cancers.妇科癌症中的铜稳态与铜死亡
Front Cell Dev Biol. 2024 Sep 25;12:1459183. doi: 10.3389/fcell.2024.1459183. eCollection 2024.
8
Cope with copper: From molecular mechanisms of cuproptosis to copper-related kidney diseases.应对铜:从铜死亡的分子机制到与铜相关的肾脏疾病。
Int Immunopharmacol. 2024 May 30;133:112075. doi: 10.1016/j.intimp.2024.112075. Epub 2024 Apr 24.
9
Merestinib inhibits cuproptosis by targeting NRF2 to alleviate acute liver injury.美瑞替尼通过靶向NRF2抑制铜死亡以减轻急性肝损伤。
Free Radic Biol Med. 2025 Mar 1;229:68-81. doi: 10.1016/j.freeradbiomed.2025.01.029. Epub 2025 Jan 15.
10
Mitochondrial-Targeted Copper Delivery for Cuproptosis-Based Synergistic Cancer Therapy.基于铜死亡的协同癌症治疗的靶向线粒体递铜。
Adv Healthc Mater. 2024 Jul;13(18):e2304522. doi: 10.1002/adhm.202304522. Epub 2024 Mar 31.

本文引用的文献

1
Advances in chromone-based copper(ii) Schiff base complexes: synthesis, characterization, and versatile applications in pharmacology and biomimetic catalysis.基于色酮的铜(II)席夫碱配合物的研究进展:合成、表征及其在药理学和仿生催化中的多种应用
RSC Adv. 2024 May 28;14(24):17102-17139. doi: 10.1039/d4ra00590b. eCollection 2024 May 22.
2
SP1/CTR1-mediated oxidative stress-induced cuproptosis in intervertebral disc degeneration.SP1/CTR1 介导的氧化应激诱导椎间盘退变中的铜死亡。
Biofactors. 2024 Sep-Oct;50(5):1009-1023. doi: 10.1002/biof.2052. Epub 2024 Apr 10.
3
Enzyme Core Spherical Nucleic Acid That Enables Enhanced Cuproptosis and Antitumor Immune Response through Alleviating Tumor Hypoxia.
通过缓解肿瘤缺氧实现增强铜死亡和抗肿瘤免疫反应的酶核心球形核酸
J Am Chem Soc. 2024 May 22;146(20):13805-13816. doi: 10.1021/jacs.3c14247. Epub 2024 Mar 29.
4
mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia.突变为人类急性髓系白血病提供了对铜载体的遗传易感性。
Sci Adv. 2024 Mar 22;10(12):eadl4018. doi: 10.1126/sciadv.adl4018.
5
The copper transporter, SLC31A1, transcriptionally activated by ELF3, imbalances copper homeostasis to exacerbate cisplatin-induced acute kidney injury through mitochondrial dysfunction.铜转运蛋白 SLC31A1 受 ELF3 转录激活,导致铜稳态失衡,通过线粒体功能障碍加剧顺铂诱导的急性肾损伤。
Chem Biol Interact. 2024 Apr 25;393:110943. doi: 10.1016/j.cbi.2024.110943. Epub 2024 Mar 9.
6
Glutathione Induced In situ Synthesis of Cu Single-Atom Nanozymes with Anaerobic Glycolysis Metabolism Interference for Boosting Cuproptosis.谷胱甘肽诱导原位合成具有抗糖酵解代谢干扰能力的 Cu 单原子纳米酶以增强铜死亡
Angew Chem Int Ed Engl. 2024 Apr 24;63(18):e202402397. doi: 10.1002/anie.202402397. Epub 2024 Mar 11.
7
Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway.二硫苏糖醇联合抗 PD-1/PD-L1 抗体通过 ATP7B 消除 NSCLC 耐药并调控 HIF-1 信号通路
Int J Mol Med. 2024 Feb;53(2). doi: 10.3892/ijmm.2023.5343. Epub 2024 Jan 8.
8
PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores.PDE3B 调节 KRT6B 并增加膀胱癌细胞对铜载体的敏感性。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):4911-4925. doi: 10.1007/s00210-023-02928-1. Epub 2024 Jan 2.
9
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.四硫钼酸铵对健康志愿者和 Wilson 病患者铜代谢的影响。
J Hepatol. 2024 Apr;80(4):586-595. doi: 10.1016/j.jhep.2023.11.023. Epub 2023 Dec 10.
10
LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma.LINC02362/hsa-miR-18a-5p/FDX1轴抑制肝细胞癌的增殖并驱动其铜死亡及对奥沙利铂的敏感性。
Am J Cancer Res. 2023 Nov 15;13(11):5590-5609. eCollection 2023.